Semax
Semax is a synthetic heptapeptide analog of ACTH(4-10) studied in nootropic and neurotrophic research models.
"Approved in Russia Since the 1990s." That's a Fact About Russia, Not About Semax.
I sell Semax, and when I followed the claims about it back to their sources, most of them stopped within two clicks. Here's how to tell which ones stop where.
"It's an Approved Drug in Russia." That's the Weakest Argument for Semax, Not the Strongest.
Semax has a real evidence base, which is exactly what makes it easy to overstate: almost none of it was collected in healthy people at a desk, and almost nobody outside its home research tradition has checked it.
Semax Isn't Under-Researched. It's Under-Translated.
Decades of work exists on this peptide. Almost nothing an English reader can actually open says a word about human cognition, and I sell the stuff.
Semax Has Been Used Clinically for Decades. That's a Claim About Russia, Not About Cognition.
The most convincing sentence in the Semax conversation is a fact about a healthcare system, and buyers keep mistaking it for evidence about a molecule.
Everyone Opens With "Semax Is Approved in Russia." Approval and Replication Are Two Different Columns.
A three-column test for reading any compound whose evidence sits behind a language border, and what the English-language literature on Semax actually contains.
Semax Is Approved in Russia. That's a Fact About a Regulator, Not a Result.
I went looking for the human trial I could hand you and came back with mice, a negative result, and one honest reason the Western data is thin.
How it is thought to work
BDNF-related and neuro-signaling pathways.
Semax is a small synthetic peptide derived from a stress hormone (ACTH) that appears to boost brain plasticity signals (especially BDNF) and modulate neurotransmitter systems, with its strongest measurable effects seen when the brain is under stress, injury, or heavy cognitive load rather than at rest.
Reported side effects
The most commonly reported side effects are nasal discoloration (in about 10% of intranasal users), nasal irritation, anxiety or overstimulation (especially with stimulants or late-day use), sleep disruption, and elevated blood sugar in diabetics, though overall human safety data remain very limited.
Who should avoid it
People with diabetes, those who are pregnant or breastfeeding, individuals prone to anxiety, and anyone taking psychiatric or stimulant medications should avoid Semax outside of direct clinician supervision.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Semax or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 0.6 to 1.5 mg/day · Low: sub-milligram per administration · High: up to ~1 mg/kg | Daily administration, often divided into morning and afternoon doses10-14 days for standard short course, 4-6 weeks for extended cognitive course · 4-6 weeks on, 2-4 weeks off | Intranasal solution, Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). Standard dosing for Semax is about 0.6 to 1.5 mg per day, typically split into two administrations. |
| 300-600 mcg intranasally daily (or 1-3 drops/nostril of 0.1% solution) | once or twice daily10-14 day cycles · Repeat cycles per provider direction | intranasal | Commonly published practitioner dosing range - provider confirmation required. |
| 200-600 mcg per dose (0.1% solution) for nootropic use; 3-6 mg per dose (1% solution) for stroke | 2-3 times dailyRepeatable | intranasal | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Referenced at 300-600 mcg (0.3-0.6 mg) daily in brain health protocols. Morning administration cited to carry cognitive benefit through the day. Rotation with other nootropic peptides between cycles referenced to maintain response. | Daily · Morning4 weeks on with rotation between cycles | nasal | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- Daily administration, often divided into morning and afternoon doses10-14 days for standard short course, 4-6 weeks for extended cognitive course · 4-6 weeks on, 2-4 weeks off
- Intranasal solution, Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). Standard dosing for Semax is about 0.6 to 1.5 mg per day, typically split into two administrations.
- once or twice daily10-14 day cycles · Repeat cycles per provider direction
- intranasal
- Commonly published practitioner dosing range - provider confirmation required.
- 2-3 times dailyRepeatable
- intranasal
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- Daily · Morning4 weeks on with rotation between cycles
- nasal
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- Requires reconstitution with bacteriostatic water before subcutaneous research use
- Compounded intranasal solution/spray · Compounded intranasal solution - no reconstitution required
Common questions
What is Semax peptide?
Semax is a synthetic seven-amino-acid peptide derived from a fragment of adrenocorticotropic hormone (ACTH) and is commonly studied as an intranasal nootropic and neuroprotective peptide.
What does Semax do?
Semax is reported to nudge brain plasticity programs and stress-response biology, associated with increased BDNF and TrkB signaling.
Is Semax FDA-approved?
No, Semax is not an FDA-approved drug in the United States.
What is a typical Semax dosage in research planning?
Total daily intranasal amounts commonly fall around 0.6 to 1.5 mg per day, divided across two administrations.
Selank vs Semax — what is the difference?
Semax is associated with cognitive activation and neuroprotection, while Selank is associated with anxiolytic and stress-modulating effects.
Is Semax nasal spray legal in the UK?
Semax is not authorized as a medicine by the UK Medicines and Healthcare products Regulatory Agency.
Can Semax and Selank be used together?
Combining Semax and Selank is a research-community planning concept but is not clinically validated.
How fast does Semax work?
Intranasal Semax is described as fast-onset, with same-day effects on attention or task initiation reported.
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for Semax as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.